COVID-19 and autoimmune bullous diseases: Lessons learned
Both COVID-19 and autoimmune bullous diseases represent potentially life-threatening conditions. Autoimmunity has been a special focus during the COVID-19 pandemic considering the possible detrimental mutual influence between COVID-19 and autoimmune disorders as well as their supposed induction or t...
Gespeichert in:
| Veröffentlicht in: | Autoimmunity reviews 2023-04, Vol.22 (4), p.103286, Article 103286 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 103286 |
| container_title | Autoimmunity reviews |
| container_volume | 22 |
| creator | Kasperkiewicz, Michael Woodley, David T. |
| description | Both COVID-19 and autoimmune bullous diseases represent potentially life-threatening conditions. Autoimmunity has been a special focus during the COVID-19 pandemic considering the possible detrimental mutual influence between COVID-19 and autoimmune disorders as well as their supposed induction or triggering by SARS-CoV-2 vaccines. There is a growing need to assess the impact of the current pandemic particularly in patients with autoimmune bullous diseases requiring potent and long-term immunosuppressive treatments. This review provides the relevant state-of-the-art knowledge, including our own research, about immunobullous diseases in relation to COVID-19 and summarizes expert perspectives on their management throughout the pandemic. |
| doi_str_mv | 10.1016/j.autrev.2023.103286 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9893837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1568997223000204</els_id><sourcerecordid>S1568997223000204</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-6c9b2327251dd892daeb6d7d0c120222888f62365554e034963f1910c25c9b943</originalsourceid><addsrcrecordid>eNp9kNtKAzEQhoMotlbfQGRfYGsOu9nEC0HqqVDojXobssmspuyhJN2Cb2_Kaq03XmXI8P0z8yF0SfCUYMKvV1PdbzxspxRTFr8YFfwIjUnORSplQY8P6hE6C2GFIyapPEUjxgsmZE7GSM6Wb_P7lMhEtzaJiZ1rmr6FpOzruutDYl0AHSDcJAsIoWtDUoP2LdhzdFLpOsDF9ztBr48PL7PndLF8ms_uFqnJONuk3MiSMlrQnFgrJLUaSm4Liw2Ji1MqhKg4ZTzP8wwwyyRnFZEEG5pHUmZsgm6H3HVfNmANtBuva7X2rtH-U3Xaqb-d1n2o926rpJBMsCIGZEOA8V0IHqo9S7DaqVQrNahUO5VqUBmxq8O5e-jH3e9iEK_fOvAqGAetAes8mI2ynft_whd--oZJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>COVID-19 and autoimmune bullous diseases: Lessons learned</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Kasperkiewicz, Michael ; Woodley, David T.</creator><creatorcontrib>Kasperkiewicz, Michael ; Woodley, David T.</creatorcontrib><description>Both COVID-19 and autoimmune bullous diseases represent potentially life-threatening conditions. Autoimmunity has been a special focus during the COVID-19 pandemic considering the possible detrimental mutual influence between COVID-19 and autoimmune disorders as well as their supposed induction or triggering by SARS-CoV-2 vaccines. There is a growing need to assess the impact of the current pandemic particularly in patients with autoimmune bullous diseases requiring potent and long-term immunosuppressive treatments. This review provides the relevant state-of-the-art knowledge, including our own research, about immunobullous diseases in relation to COVID-19 and summarizes expert perspectives on their management throughout the pandemic.</description><identifier>ISSN: 1568-9972</identifier><identifier>EISSN: 1568-9972</identifier><identifier>EISSN: 1873-0183</identifier><identifier>DOI: 10.1016/j.autrev.2023.103286</identifier><identifier>PMID: 36738951</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Autoimmune Diseases - epidemiology ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 Vaccines ; Humans ; Pandemics ; Pemphigoid ; Pemphigoid, Bullous ; Pemphigus ; SARS-CoV-2</subject><ispartof>Autoimmunity reviews, 2023-04, Vol.22 (4), p.103286, Article 103286</ispartof><rights>2023 Elsevier B.V.</rights><rights>Copyright © 2023 Elsevier B.V. All rights reserved.</rights><rights>2023 Elsevier B.V. All rights reserved. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-6c9b2327251dd892daeb6d7d0c120222888f62365554e034963f1910c25c9b943</citedby><cites>FETCH-LOGICAL-c463t-6c9b2327251dd892daeb6d7d0c120222888f62365554e034963f1910c25c9b943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.autrev.2023.103286$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36738951$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kasperkiewicz, Michael</creatorcontrib><creatorcontrib>Woodley, David T.</creatorcontrib><title>COVID-19 and autoimmune bullous diseases: Lessons learned</title><title>Autoimmunity reviews</title><addtitle>Autoimmun Rev</addtitle><description>Both COVID-19 and autoimmune bullous diseases represent potentially life-threatening conditions. Autoimmunity has been a special focus during the COVID-19 pandemic considering the possible detrimental mutual influence between COVID-19 and autoimmune disorders as well as their supposed induction or triggering by SARS-CoV-2 vaccines. There is a growing need to assess the impact of the current pandemic particularly in patients with autoimmune bullous diseases requiring potent and long-term immunosuppressive treatments. This review provides the relevant state-of-the-art knowledge, including our own research, about immunobullous diseases in relation to COVID-19 and summarizes expert perspectives on their management throughout the pandemic.</description><subject>Autoimmune Diseases - epidemiology</subject><subject>COVID-19</subject><subject>COVID-19 - epidemiology</subject><subject>COVID-19 Vaccines</subject><subject>Humans</subject><subject>Pandemics</subject><subject>Pemphigoid</subject><subject>Pemphigoid, Bullous</subject><subject>Pemphigus</subject><subject>SARS-CoV-2</subject><issn>1568-9972</issn><issn>1568-9972</issn><issn>1873-0183</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kNtKAzEQhoMotlbfQGRfYGsOu9nEC0HqqVDojXobssmspuyhJN2Cb2_Kaq03XmXI8P0z8yF0SfCUYMKvV1PdbzxspxRTFr8YFfwIjUnORSplQY8P6hE6C2GFIyapPEUjxgsmZE7GSM6Wb_P7lMhEtzaJiZ1rmr6FpOzruutDYl0AHSDcJAsIoWtDUoP2LdhzdFLpOsDF9ztBr48PL7PndLF8ms_uFqnJONuk3MiSMlrQnFgrJLUaSm4Liw2Ji1MqhKg4ZTzP8wwwyyRnFZEEG5pHUmZsgm6H3HVfNmANtBuva7X2rtH-U3Xaqb-d1n2o926rpJBMsCIGZEOA8V0IHqo9S7DaqVQrNahUO5VqUBmxq8O5e-jH3e9iEK_fOvAqGAetAes8mI2ynft_whd--oZJ</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>Kasperkiewicz, Michael</creator><creator>Woodley, David T.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20230401</creationdate><title>COVID-19 and autoimmune bullous diseases: Lessons learned</title><author>Kasperkiewicz, Michael ; Woodley, David T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-6c9b2327251dd892daeb6d7d0c120222888f62365554e034963f1910c25c9b943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Autoimmune Diseases - epidemiology</topic><topic>COVID-19</topic><topic>COVID-19 - epidemiology</topic><topic>COVID-19 Vaccines</topic><topic>Humans</topic><topic>Pandemics</topic><topic>Pemphigoid</topic><topic>Pemphigoid, Bullous</topic><topic>Pemphigus</topic><topic>SARS-CoV-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kasperkiewicz, Michael</creatorcontrib><creatorcontrib>Woodley, David T.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Autoimmunity reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kasperkiewicz, Michael</au><au>Woodley, David T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 and autoimmune bullous diseases: Lessons learned</atitle><jtitle>Autoimmunity reviews</jtitle><addtitle>Autoimmun Rev</addtitle><date>2023-04-01</date><risdate>2023</risdate><volume>22</volume><issue>4</issue><spage>103286</spage><pages>103286-</pages><artnum>103286</artnum><issn>1568-9972</issn><eissn>1568-9972</eissn><eissn>1873-0183</eissn><abstract>Both COVID-19 and autoimmune bullous diseases represent potentially life-threatening conditions. Autoimmunity has been a special focus during the COVID-19 pandemic considering the possible detrimental mutual influence between COVID-19 and autoimmune disorders as well as their supposed induction or triggering by SARS-CoV-2 vaccines. There is a growing need to assess the impact of the current pandemic particularly in patients with autoimmune bullous diseases requiring potent and long-term immunosuppressive treatments. This review provides the relevant state-of-the-art knowledge, including our own research, about immunobullous diseases in relation to COVID-19 and summarizes expert perspectives on their management throughout the pandemic.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>36738951</pmid><doi>10.1016/j.autrev.2023.103286</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1568-9972 |
| ispartof | Autoimmunity reviews, 2023-04, Vol.22 (4), p.103286, Article 103286 |
| issn | 1568-9972 1568-9972 1873-0183 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9893837 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Autoimmune Diseases - epidemiology COVID-19 COVID-19 - epidemiology COVID-19 Vaccines Humans Pandemics Pemphigoid Pemphigoid, Bullous Pemphigus SARS-CoV-2 |
| title | COVID-19 and autoimmune bullous diseases: Lessons learned |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A35%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20and%20autoimmune%20bullous%20diseases:%20Lessons%20learned&rft.jtitle=Autoimmunity%20reviews&rft.au=Kasperkiewicz,%20Michael&rft.date=2023-04-01&rft.volume=22&rft.issue=4&rft.spage=103286&rft.pages=103286-&rft.artnum=103286&rft.issn=1568-9972&rft.eissn=1568-9972&rft_id=info:doi/10.1016/j.autrev.2023.103286&rft_dat=%3Celsevier_pubme%3ES1568997223000204%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/36738951&rft_els_id=S1568997223000204&rfr_iscdi=true |